Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 13/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 13/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501013 | 1.00 | RIPK1 (0.41) | RIPK1JAK2NTRK1HSD11B1GRM5 | |
| SCHEMBL23501030 | 0.85 | NTRK1 (0.49) | RIPK1JAK2NTRK1JAK1 | |
| SCHEMBL23501031 | 0.85 | NTRK1 (0.49) | RIPK1JAK2NTRK1JAK1 | |
| SCHEMBL24993318 | 0.80 | RIPK1 (0.47) | RIPK1JAK2NTRK1GRM5PRCP | |
| SCHEMBL21587443 | 0.74 | NTRK1 (0.51) | JAK2NTRK1JAK1 | |
| SCHEMBL23501106 | 0.74 | RIPK1 (0.43) | RIPK1JAK2NTRK1GRM5PRCP | |
| SCHEMBL20602710 | 0.74 | NTRK1 (0.66) | JAK2NTRK1JAK1 | |
| SCHEMBL21219502 | 0.74 | NTRK1 (0.66) | JAK2NTRK1JAK1 | |
| SCHEMBL23500994 | 0.73 | RIPK1 (0.43) | RIPK1JAK2NTRK1GRM5PRCP | |
| SCHEMBL2599290 | 0.73 | NTRK1 (0.68) | JAK2NTRK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428433-B2 | Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20230044722-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4074715-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-112979679-B | Fluoroheterocyclic derivative having macrocyclic structure and use thereof | 成都倍特药业股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112979679-A | Fluoroheterocyclic derivative having macrocyclic structure and use thereof | 成都倍特药业股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021115401-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115401-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428433-B2 | Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof | FRK, BRAF, ERBB3 | RIPK1 588/4885JAK2 106/4885NTRK1 4/4885 |
| US-20230044722-A1 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | FRK, BRAF, ERBB3 | RIPK1 588/4885JAK2 106/4885NTRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.